The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The promise of immunotherapies in T-cell lymphoma
T-cell lymphomas are aggressive diseases that do not respond to cytotoxic chemotherapy the way B-cell lymphomas do, resulting in a poor prognosis. Stefan Barta, MD, MS, University of Pennsylvania, Philadelphia, PA, discusses the potential of immunotherapies to revolutionize T-cell lymphoma treatment, focusing on bispecific antibodies, CAR T-cell therapy, and checkpoint inhibitors. Dr Barta explores their mechanisms of action, benefits, and limitations. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
